What is HC Wainwright’s Estimate for ACRV FY2030 Earnings?

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) – Stock analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Acrivon Therapeutics in a research note issued on Friday, February 27th. HC Wainwright analyst E. Bodnar forecasts that the company will post earnings of ($0.08) per share for the year. HC Wainwright has a “Buy” rating and a $19.00 price objective on the stock. The consensus estimate for Acrivon Therapeutics’ current full-year earnings is ($2.49) per share.

Several other analysts also recently issued reports on ACRV. Weiss Ratings reissued a “sell (d-)” rating on shares of Acrivon Therapeutics in a research note on Monday, December 29th. Piper Sandler increased their price objective on Acrivon Therapeutics from $6.00 to $8.00 and gave the company an “overweight” rating in a report on Friday, January 9th. Finally, Wall Street Zen cut shares of Acrivon Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Acrivon Therapeutics has an average rating of “Moderate Buy” and an average target price of $11.67.

Acrivon Therapeutics Price Performance

ACRV stock opened at $1.51 on Monday. The firm has a market capitalization of $47.66 million, a P/E ratio of -0.71 and a beta of 1.79. Acrivon Therapeutics has a 52-week low of $1.05 and a 52-week high of $5.75. The company’s 50 day simple moving average is $1.94 and its 200-day simple moving average is $1.92.

Insider Buying and Selling at Acrivon Therapeutics

In other news, CEO Peter Blume-Jensen bought 49,000 shares of the company’s stock in a transaction dated Wednesday, January 14th. The stock was bought at an average price of $1.68 per share, for a total transaction of $82,320.00. Following the completion of the transaction, the chief executive officer directly owned 2,095,771 shares in the company, valued at $3,520,895.28. The trade was a 2.39% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders acquired a total of 67,832 shares of company stock worth $114,534 in the last ninety days. Insiders own 8.50% of the company’s stock.

Hedge Funds Weigh In On Acrivon Therapeutics

Several large investors have recently bought and sold shares of ACRV. Quadrature Capital Ltd bought a new stake in shares of Acrivon Therapeutics during the 2nd quarter valued at $26,000. Focus Partners Wealth bought a new stake in shares of Acrivon Therapeutics in the 3rd quarter valued at about $36,000. Schonfeld Strategic Advisors LLC bought a new stake in shares of Acrivon Therapeutics in the 4th quarter valued at about $40,000. Vermillion & White Wealth Management Group LLC acquired a new stake in shares of Acrivon Therapeutics in the 4th quarter valued at approximately $44,000. Finally, Invesco Ltd. bought a new position in Acrivon Therapeutics during the 1st quarter worth approximately $72,000. 71.62% of the stock is currently owned by institutional investors and hedge funds.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics (NASDAQ:ACRV) is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.

The company’s lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.